New gel treatment aims to reduce 'Off' time in advanced Parkinson's
Disease control
Recruiting now
This study follows about 215 adults with advanced Parkinson's disease who are switching from a subcutaneous medication to LECIGON, an intestinal gel. The main goal is to see if LECIGON reduces daily 'OFF' time (when symptoms return) after 12 months. Participants will be monitored…
Sponsor: Britannia Pharmaceuticals Ltd. • Aim: Disease control
Last updated May 17, 2026 11:08 UTC